For Healthcare Professionals

A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies


About the study

To evaluate the safety and tolerability of escalating doses of ERAS-007 in combination with other cancer therapies in study participants with advanced GI malignancies. To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007 administered in combination with other cancer therapies. To evaluate the antitumor activity of ERAS-007 in combination with other cancer therapies. To evaluate the PK profiles of ERAS-007 and other cancer therapies when administered in combination.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Inclusion Criteria:

  1. Age ≥ 18 years.
  2. Willing and able to give written informed consent.
  3. Have histologically or cytologically confirmed metastatic CRC harboring applicable mutation(s) (e.g., BRAF V600E; KRAS or NRAS mutations) or metastatic PDAC harboring KRAS mutation based on an analytically validated assay performed on tumor tissue in a certified testing laboratory.
  4. Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
  5. Adequate bone marrow and organ function.
  6. Have ECOG performance status of 0 or 1.
  7. Willing to comply with all protocol-required visits, assessments, and procedures.
  8. Able to swallow oral medication.


Exclusion Criteria:

  1. Prior therapy with a RAS, MEK, or ERK inhibitor. Depending on which treatment arm the patient is assigned, other therapies could also be prohibitive.
  2. Anti-cancer therapy ≤ 21 days or 4 half-lives prior to first dose of study drug, whichever is shorter.
  3. Palliative radiation ≤ 7 days prior to first dose of study drug.
  4. Symptomatic brain metastasis or leptomeningeal disease.
  5. Gastrointestinal conditions that may affect absorption of oral medications
  6. Active infection requiring systemic therapy, or a known history of HIV infection, hepatitis B virus, or hepatitis C virus.
  7. History of chronic inflammatory bowel disease or Crohn's disease requiring medical intervention (immunomodulatory or immunosuppressive medications or surgery) ≤ 12 months prior to first study drug dose.
  8. Active, clinically significant interstitial lung disease or pneumonitis.
  9. Impaired cardiovascular function or clinically significant cardiovascular disease.
  10. History of thromboembolic or cerebrovascular events ≤ 6 months prior to first dose.
  11. Major surgery within 28 days of enrollment, or anticipation of major surgery during study treatment.
  12. Known intolerance or contraindication to encorafenib, cetuximab, or palbociclib.
  13. Pregnant or breastfeeding women.
  14. Any evidence of severe or uncontrolled systemic disease or evidence of any other significant clinical disorder or laboratory finding that renders the patient inappropriate to participate in the study.
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details


Metastatic Colorectal Cancer,Metastatic Pancreatic Ductal Adenocarcinoma

Age (in years)

18 - 99


Phase 1/Phase 2

Participants needed


Est. Completion Date

Dec 31, 2024

Treatment type



Erasca, Inc. identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.